TY - JOUR
T1 - Improved growth velocity of a patient with Noonan-like syndrome with loose anagen hair (NS/LAH) without growth hormone deficiency by low-dose growth hormone therapy
AU - Takasawa, Kei
AU - Takishima, Shigeru
AU - Morioka, Chikako
AU - Nishioka, Masato
AU - Ohashi, Hirofumi
AU - Aoki, Yoko
AU - Shimohira, Masayuki
AU - Kashimada, Kenichi
AU - Morio, Tomohiro
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Noonan-like syndrome with loose anagen hair (NS/LAH; OMIM 607721) is caused by a heterozygous c.4A>G mutation in SHOC2. Most cases exhibit both growth hormone deficiency (GHD) and growth hormone insensitivity (GHI) and thus require a high dose of growth hormone (GH) therapy (e.g., 35-40μg/kg/day). We report on a genetically diagnosed NS/LAH patient manifesting severe short stature (-3.85 SDs) with low serum level of IGF1, 30ng/ml. The peak levels of GH stimulation tests were within the normal range, and GHI was not observed in the IGF1 generation test. However, with low-dose GH therapy (25μg/kg/day) for two years, IGF1 level and height were remarkably improved (IGF1: 117ng/ml, height SDs: -2.20 SDs). Further, catch-up of motor development and improvement of the proportion of extending limbs to trunk were observed (the Developmental Quotient score increased from 68 to 98 points, and the relative sitting height ratio decreased from 0.62 to 0.57). Our results suggest that endocrinological causes for short stature are variable in NS/LAH and that GH therapy should be considered as a possible treatment for delayed development in NS/LAH.
AB - Noonan-like syndrome with loose anagen hair (NS/LAH; OMIM 607721) is caused by a heterozygous c.4A>G mutation in SHOC2. Most cases exhibit both growth hormone deficiency (GHD) and growth hormone insensitivity (GHI) and thus require a high dose of growth hormone (GH) therapy (e.g., 35-40μg/kg/day). We report on a genetically diagnosed NS/LAH patient manifesting severe short stature (-3.85 SDs) with low serum level of IGF1, 30ng/ml. The peak levels of GH stimulation tests were within the normal range, and GHI was not observed in the IGF1 generation test. However, with low-dose GH therapy (25μg/kg/day) for two years, IGF1 level and height were remarkably improved (IGF1: 117ng/ml, height SDs: -2.20 SDs). Further, catch-up of motor development and improvement of the proportion of extending limbs to trunk were observed (the Developmental Quotient score increased from 68 to 98 points, and the relative sitting height ratio decreased from 0.62 to 0.57). Our results suggest that endocrinological causes for short stature are variable in NS/LAH and that GH therapy should be considered as a possible treatment for delayed development in NS/LAH.
KW - GH therapy
KW - GHD
KW - GHI
KW - NS/LAH
KW - SHOC2
UR - http://www.scopus.com/inward/record.url?scp=84941261719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941261719&partnerID=8YFLogxK
U2 - 10.1002/ajmg.a.37191
DO - 10.1002/ajmg.a.37191
M3 - Article
C2 - 26096762
AN - SCOPUS:84941261719
SN - 1552-4825
VL - 167
SP - 2425
EP - 2429
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 10
ER -